ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer

Ítems similars

• ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer
  per: Petit, Robert G, et al.
  Publicat: (2014)
• Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy
  per: Molli, Poonam, et al.
  Publicat: (2013)
• Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer
  per: Cohen, Ezra EW, et al.
  Publicat: (2015)
• A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
  per: Basu, Partha, et al.
  Publicat: (2018)
• High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer
  per: Ghamande, Sharad, et al.
  Publicat: (2015)